GLP-1 Evidence

Članak

GLP-1 i osteoartritis koljena: što pokazuje istraživanje

Mršavljenje se oduvijek preporučuje kod osteoartritisa koljena, a bilo je samo pitanje vremena kada će skupina lijekova koja pouzdano proizvodi gubitak tjelesne mase od 15–20% biti ispitana u tom kontekstu. Sada je jedno ispitivanje provedeno. Evo što je pokazalo, a što nije.

Updated 4 min read 40 citations

Unutrašnjost neiskorištene bolničke sobe s krevetom, stazom za dizalo na stropu i sjedećim mjestima
Official Navy Page from United States of America MC2 Todd… · Public domain · Wikimedia Commons

Zašto je ovo pitanje smisleno

Osteoartritis koljena nije čisto mehaničko trošenje, no mehaničko opterećenje dio je slike, a manja tjelesna masa znači manje opterećenje na zglob koji nosi tjelesnu masu — dugogodišnje ortopedsko obrazloženje, a ne nalaz iz GLP-1 ispitivanja. Pretilost je s osteoartritisom povezana i putem metaboličkih i upalnih mehanizama koji nadilaze puko opterećenje — masno je tkivo metabolički aktivno, a sistemska upala vjerojatan je drugi put kojim bi mršavljenje moglo pomoći zglobovima koji uopće ne nose tjelesnu masu, poput ruku. Lijek koji proizvodi i znatan gubitak tjelesne mase i, prema mehanističkim pregledima ove skupine lijekova, promjene u regulaciji apetita i energije putem središnjih i perifernih mehanizama, razuman je kandidat za testiranje [37].

Ispitivanje

Randomizirano, placebom kontrolirano ispitivanje testiralo je semaglutide jednom tjedno posebno kod osoba s pretilošću i osteoartritisom koljena [17]. Riječ je o drukčijoj populaciji i drukčijoj primarnoj mjeri ishoda nego u ispitivanjima pretilosti sa semaglutide i tirzepatide obrađenima na drugim mjestima ovog sajta: ovdje su mjereni ishodi bili bol i tjelesna funkcija kod osteoartritisa, ne samo tjelesna masa. Ispitivanje je izvijestilo o većem poboljšanju u skupini koja je primala semaglutide u odnosu na skupinu s placebom, i to na mjerama boli i mjerama funkcije, uz gubitak tjelesne mase koji se dosljedno bilježi uz ovaj lijek i u drugim ispitivanjima. To je doista novi tip rezultata za ovu skupinu lijekova — randomizirano ispitivanje s ishodom specifičnim za zglob, a ne zaključak izveden iz ispitivanja mršavljenja koja su usput pitala o boli kao sekundarnoj mjeri.

Tri mehanizma, tri različite razine dokaza

PutŠto to podupireKoliko je to čvrsto
Manje mehaničko opterećenje zbog mršavljenjaDugogodišnje ortopedsko obrazloženje za mršavljenje kod osteoartritisa koljena općenitoNije nalaz specifičan za GLP-1, i izvan je skupa referenci ovog sajta
Izravni dokazi iz ispitivanja kod osteoartritisa koljenaJedno randomizirano, placebom kontrolirano ispitivanje upravo u ovoj populaciji [17]Stvarno, ali jedno jedino ispitivanje
Gubitak mišićne mase koja podupire zglob tijekom liječenjaPodaci o sastavu tijela i nemasnoj masi iz GLP-1 ispitivanja općenito [3] [7]Stvarno, i djeluje u suprotnom smjeru

Taj treći redak bitan je i lako se previdi u izvještavanju o ovom ispitivanju. Nemasna masa — uključujući mišiće koji stabiliziraju koljeni zglob — čini otprilike četvrtinu do trećinu tjelesne mase izgubljene uz ove lijekove, nalaz koji ovaj sajt detaljno obrađuje na svojoj stranici o gubitku mišićne mase. Neto rezultat ispitivanja o osteoartritisu ipak je bio pozitivan po pitanju boli i funkcije, što znači da izgubljena mišićna masa nije nadmašila korist od smanjenog opterećenja i mogućeg protuupalnog učinka. No to znači da je pošten opis učinka ovog lijeka na zglob „razlika između dviju stvari koje vuku u suprotnim smjerovima”, a ne jednostavno „mršavljenje pomaže zglobovima”.

Što vam ispitivanje ne govori

Jedno ispitivanje s jednim lijekom, kod osoba koje su pri uključivanju imale pretilost i dijagnosticiran osteoartritis koljena, ne utvrđuje učinak za cijelu skupinu lijekova, za druge zglobove, za osobe bez pretilosti ili za dugoročne strukturne ishode poput volumena hrskavice. Također vam ne govori koliko je korist trajna nakon prekida uzimanja lijeka — pitanje na koje stranica o prekidu terapije ovog sajta već daje nepovoljan odgovor za samu tjelesnu masu, a ne postoje posebni podaci praćenja za osteoartritis koji bi rekli slijedi li olakšanje boli u zglobu isti obrazac povratka.

Što ovo znači u praksi

Ako bol u koljenu i višak tjelesne mase koegzistiraju, ovo je sada još jedan dokaz — specifičan, randomiziran — da se gubitak tjelesne mase izazvan GLP-1 lijekom može pretočiti u mjerljivu korist za zglob, a ne samo u broj na vagi. To nije dokaz da ovi lijekovi liječe osteoartritis neovisno o mršavljenju, niti je dokaz za druge zglobove ili druge populacije. Profil nuspojava i pitanje gubitka mišićne mase koji vrijede za svaku uporabu ove skupine lijekova vrijede i ovdje; nijedno se ne mijenja samo zato što je ciljani ishod zglob, a ne struk.

Česta pitanja

Liječi li semaglutide osteoartritis, ili samo pomaže putem mršavljenja?
Ispitivanje ne razdvaja ta dva učinka. Testiralo je lijek naspram placeba i mjerilo bol i funkciju te utvrdilo korist; nije testiralo postoji li učinak neovisno o promjeni tjelesne mase [17].
Uzrokuje li lijek gubitak mišićne mase posebno oko koljena?
Objavljeni podaci o sastavu tijela mjere ukupnu nemasnu masu, a ne mišiće na određenom zglobu, pa na to ne mogu precizno odgovoriti — no pokazuju značajan gubitak nemasne mase ukupno tijekom liječenja [3].
Je li ovo ispitivanje provedeno samo sa semaglutide, ili vrijedi i za tirzepatide?
Za sada je samo semaglutide testiran u ovoj specifičnoj populaciji i s ovim ishodom. Veći prosječni gubitak tjelesne mase uz tirzepatide (vidi stranicu o tirzepatide) razuman je temelj za očekivanje usporedivog ili većeg učinka, no to je ekstrapolacija, a ne dokaz iz ispitivanja.
Ako prestanem uzimati lijek, nestaje li korist za zglob zajedno s tjelesnom masom?
Za to pitanje ne postoje posebni dugoročni podaci praćenja. S obzirom na to koliko se dosljedno tjelesna masa vraća nakon prekida terapije (vidi što se događa kada prestanete), bilo bi razumno očekivati da simptomi u zglobu prate tjelesnu masu, no to nije izravno izmjereno.
Labavi okrugli tableti s otisnutim identifikacijskim kodom, viđeni odozgo
Larry D. Moore · CC BY 4.0 · Wikimedia Commons
Dokazi iza ove stranice Stogani grafikon koji prikazuje sastav 40 publikacija citiranih na ovoj stranici prema vrsti studije. 13215meta-analysis (13)randomised trial (21)review (5)other (1)
40 publikacija, 2016–2026. To je mješavina koja uključuje i ispitivanja i sinteze, što je pozicija iz koje je tvrdnja o uzroku razumna. Izvor: vlastita lista citata ove stranice, u nastavku.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  2. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  3. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  4. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  5. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  6. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  7. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  8. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management Hiramoto B, McCarty TR, Lodhia NA, et al. · The American journal of gastroenterology · 2024 · Meta-analysis DOIPubMed 38634551Full text
  9. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  10. Weight loss efficiency and safety of tirzepatide: A Systematic review Lin F, Yu B, Ling B, et al. · PloS one · 2023 · Meta-analysis DOIPubMed 37141329Full text
  11. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  12. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  13. Anti-diabetic drugs and weight loss in patients with type 2 diabetes Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacological research · 2021 · Systematic review DOIPubMed 34302978
  14. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  15. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  16. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  17. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  18. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Look M, Dunn JP, Kushner RF, et al. · Diabetes, obesity & metabolism · 2025 · Randomised controlled trial DOIPubMed 39996356Full text
  19. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  20. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  21. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, et al. · Molecular metabolism · 2023 · Randomised controlled trial DOIPubMed 37364710Full text
  22. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  23. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes Silver HJ, Olson D, Mayfield D, et al. · Diabetes, obesity & metabolism · 2023 · Randomised controlled trial DOIPubMed 37188932Full text
  24. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023 · Randomised controlled trial DOIPubMed 36857477Full text
  25. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  26. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  27. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  28. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  29. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  30. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  31. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  32. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  33. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  34. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  35. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  36. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  37. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016 · Randomised controlled trial DOIPubMed 27633186
  38. GLP-1 Receptor Agonists Rosen CJ, Ingelfinger JR · The New England journal of medicine · 2026 · Review DOIPubMed 41931049
  39. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance Bansal MB, Patton H, Morgan TR, et al. · Hepatology (Baltimore, Md.) · 2026 · Review DOIPubMed 41201884
  40. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation Moiz A, Filion KB, Tsoukas MA, et al. · The American journal of medicine · 2025 · Review DOIPubMed 39892489

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original